STINGing Cancer: Development, Clinical Application, and Targeted Delivery of STING Agonists

Area of Science:

• Immunology
• Oncology
• Nanotechnology

Background:

• Rising cancer incidence and limited conventional therapy effectiveness necessitate novel treatments.
• Immunotherapies like checkpoint inhibitors and CAR-T cells have advanced cancer care, but response rates vary.
• STING (STimulator of INterferon Genes) agonists are emerging immunomodulatory agents targeting the tumor microenvironment.

Purpose of the Study:

• To review STING agonists evaluated in clinical trials for cancer treatment.
• To discuss the impact of STING agonists on tumor-infiltrating immune cells, particularly macrophages.
• To explore emerging preclinical STING agonist candidates and nanotechnological strategies for enhanced efficacy.

Main Methods:

• Review of clinical trial data for selected STING agonists.
• Analysis of STING agonist effects on cytokine profiles and immune cell function within the tumor microenvironment.
• Investigation of preclinical studies on novel STING agonists and nanotechnology-based delivery systems.

Main Results:

• STING agonists show potential in preclinical models but clinical translation faces challenges.
• Activation of the STING pathway can alter the tumor microenvironment and reshape immune cell functions.
• Nanotechnology offers a strategy to improve STING agonist potency, biodistribution, and sustained TME accumulation.

Conclusions:

• STING agonists represent a promising avenue for cancer immunotherapy, with ongoing optimization and clinical evaluation.
• Understanding STING agonist interactions with tumor-infiltrating immune cells, especially macrophages, is crucial.
• Combinational approaches using nanotechnology are key to enhancing the therapeutic efficacy of STING agonists.